Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 16/20 | 0.53 |
| ▸ | MAOA | P21397 | 15/20 | 0.53 |
| ▸ | MAOB | P27338 | 15/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21066062 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL874954 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL21066065 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL8041609 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL2766130 | 1.00 | KDM1A (0.53) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| Hydrochloric Acid SCHEMBL28632580 | 0.98 | KDM1A (0.55) | KDM1AMAOAMAOB | |
| Hydrochloric Acid SCHEMBL2073275 | 0.98 | KDM1A (0.55) | KDM1AMAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL14762539 | 0.90 | KDM1A (0.44) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL13722853 | 0.90 | KDM1A (0.44) | KDM1AMAOAMAOBMAPK1CYP2C19 | |
| SCHEMBL901505 | 0.86 | KDM1A (0.52) | KDM1AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462713-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| WO-2008090357-A2 | N, N; -SUBSTITUTED PIPERAZINES BINDING TO MELANOCORTIN RECEPTOR | PALATIN TECHNOLOGIES, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7132533-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-6967198-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK1, CHEK2, CHKA | KDM1A 1751/4885MAOA 4750/4885MAOB 4691/4885 |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | KDM1A 1684/4885MAOA 4721/4885MAOB 4589/4885 |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | KDM1A 1434/4885MAOA 4686/4885MAOB 4520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.